Bortezomib (VELCADE®)

VELCADE (bortezomib) is a type of chemotherapy called a targeted therapy.

VELCADE belongs to a class of medicines called proteasome inhibitors. It is approved by the FDA for the treatment of multiple myeloma and mantle cell lymphoma. VELCADE has been studied in many important clinical trials. It has been studied in a wide range of people, including those with renal impairment and diabetes. As a targeted therapy, VELCADE works by blocking or slowing down the action of proteasomes inside cells. The function of proteasomes is to break down proteins in both healthy and cancerous cells.